Liu Wenhua, Tretiakova Maria, Kong Juan, Turkyilmaz Muge, Li Yan Chun, Krausz Thomas
Department of Pathology, The University of Chicago Hospitals, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA.
Hum Pathol. 2006 Oct;37(10):1268-78. doi: 10.1016/j.humpath.2006.04.029. Epub 2006 Jul 27.
The kidney is not only a primary vitamin D target organ but also is a key site of vitamin D metabolism. Recent studies have shown that vitamin D has important physiologic effects on proliferation and differentiation in a variety of benign and malignant cells. Our preliminary immunohistochemical study showed that vitamin D receptor (VDR) was highly expressed in renal distal tubules and collecting ducts, whereas the renal proximal tubules and glomeruli did not express VDR. These observations led us to study the expression of VDR in various kidney tumors to determine the possible diagnostic utility of VDR. Paraffin tissue microarray (TMA) blocks were constructed containing core cylinders from clear cell (52), papillary (35), chromophobe (20), sarcomatoid (20), and metastatic (59) renal cell carcinomas (RCCs). Oncocytomas (20), normal adult kidneys (12), and normal adult adrenals (6) were also included. In addition, 30 clear cell RCCs and 3 collecting duct carcinomas were also studied using conventional sections. Furthermore, VDR messenger RNA and protein expression was also quantified using real-time reverse transcriptase-polymerase chain reaction and Western blot analysis. Vitamin D receptor was strongly positive in collecting duct carcinomas (100% [3/3], cytoplasmic), papillary RCCs (94% [33/35], cytoplasmic), chromophobe RCCs (85% [17/20], membranous), and oncocytomas (90% [18/20], cytoplasmic with perinuclear accentuation). In contrast, VDR expression was focal/weak and present only in the peripheral regions of clear cell RCCs. Vitamin D receptor was weakly positive in sarcomatoid variant RCCs (88% [14/16]) regardless of the type of associated original RCC. Overall, VDR is a discriminative marker for renal cell tumors. The preferential expression of VDR in chromophobe RCCs, oncocytomas, and collecting duct carcinomas is in agreement with the concept that these tumors differentiate toward epithelium lining the distal convoluted tubules and collecting ducts. Considering the different VDR expression patterns, VDR is a useful ancillary tool in distinguishing chromophobe RCCs from oncocytomas. In addition, the focal and much weaker VDR expression in clear cell RCCs makes VDR valuable in distinguishing clear cell RCC from other types of RCCs.
肾脏不仅是维生素D的主要靶器官,也是维生素D代谢的关键部位。最近的研究表明,维生素D对多种良性和恶性细胞的增殖和分化具有重要的生理作用。我们初步的免疫组织化学研究显示,维生素D受体(VDR)在肾远端小管和集合管中高表达,而肾近端小管和肾小球不表达VDR。这些观察结果促使我们研究VDR在各种肾肿瘤中的表达,以确定VDR可能的诊断效用。构建石蜡组织微阵列(TMA)块,其中包含来自透明细胞(52例)、乳头状(35例)、嫌色细胞(20例)、肉瘤样(20例)和转移性(59例)肾细胞癌(RCC)的核心圆柱。还纳入了嗜酸细胞瘤(20例)、正常成人肾脏(12例)和正常成人肾上腺(6例)。此外,还使用常规切片对30例透明细胞RCC和3例集合管癌进行了研究。此外,还使用实时逆转录聚合酶链反应和蛋白质印迹分析对VDR信使核糖核酸和蛋白质表达进行了定量。维生素D受体在集合管癌(100%[3/3],细胞质)、乳头状RCC(94%[33/35],细胞质)、嫌色细胞RCC(85%[17/20],膜性)和嗜酸细胞瘤(90%[18/20],细胞质且核周增强)中呈强阳性。相比之下,VDR表达呈局灶性/弱阳性,仅存在于透明细胞RCC的周边区域。无论相关原始RCC的类型如何,维生素D受体在肉瘤样变体RCC中呈弱阳性(88%[14/16])。总体而言,VDR是肾细胞肿瘤的鉴别标志物。VDR在嫌色细胞RCC、嗜酸细胞瘤和集合管癌中的优先表达与这些肿瘤向远曲小管和集合管内衬上皮分化的概念一致。考虑到不同的VDR表达模式,VDR是区分嫌色细胞RCC和嗜酸细胞瘤的有用辅助工具。此外,透明细胞RCC中VDR表达的局灶性和弱得多的特点使得VDR在区分透明细胞RCC与其他类型的RCC方面具有价值。